Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.

Unger J.

Curr Diab Rep. 2013 Oct;13(5):663-8. doi: 10.1007/s11892-013-0404-x. Review.

PMID:
23955813
2.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
3.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
4.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
5.

Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.

Hare KJ.

Dan Med Bull. 2010 Sep;57(9):B4181.

PMID:
20816021
6.

Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?

Shehadeh N, Daich E, Zuckerman-Levin N.

Pediatr Endocrinol Rev. 2014 Mar;11(3):324-7. Review.

PMID:
24716398
7.

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.

Kielgast U, Holst JJ, Madsbad S.

Curr Diabetes Rev. 2009 Nov;5(4):266-75. Review.

PMID:
19925391
8.

Differentiating incretin-based therapies for population-based health care.

Calabrese D.

Am J Manag Care. 2011 Mar;17(2 Suppl):S52-8.

9.

The incretin system and its role in type 2 diabetes mellitus.

Holst JJ, Vilsbøll T, Deacon CF.

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. doi: 10.1016/j.mce.2008.08.012. Epub 2008 Aug 20. Review.

PMID:
18786605
10.

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.

Verge D, López X.

Curr Diabetes Rev. 2010 Jul;6(4):191-200. Review.

PMID:
20380625
11.

Glucagon-like peptide-1 structure, function and potential use for NIDDM.

Gefel D, Barg Y, Zimlichman R.

Isr J Med Sci. 1997 Oct;33(10):690-5. Review.

PMID:
9397146
12.

GLP-1 receptor agonists today.

Marre M, Penfornis A.

Diabetes Res Clin Pract. 2011 Sep;93(3):317-27. doi: 10.1016/j.diabres.2011.01.004. Epub 2011 Jul 20. Review.

PMID:
21767888
13.

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.

Montanya E.

Expert Opin Pharmacother. 2012 Jul;13(10):1451-67. doi: 10.1517/14656566.2012.692777. Review.

PMID:
22725703
14.

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.

Yamagishi S, Matsui T.

Curr Pharm Des. 2011 Dec;17(38):4379-85. Review.

PMID:
22204436
15.

Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.

Wick A, Newlin K.

J Am Acad Nurse Pract. 2009 Nov;21 Suppl 1:623-30. Review.

PMID:
19900193
16.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Moon HS, Kim MK, Son MH.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z. Review.

PMID:
21811909
17.

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ.

Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.

PMID:
15155141
18.

Glucagon-like peptide 1 based therapy for type 2 diabetes.

Yu BS, Wang AR.

World J Pediatr. 2008 Feb;4(1):8-13. doi: 10.1007/s12519-008-0002-1. Review.

PMID:
18402245
19.

Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.

De León DD, Crutchlow MF, Ham JY, Stoffers DA.

Int J Biochem Cell Biol. 2006;38(5-6):845-59. Epub 2005 Sep 15. Review.

PMID:
16202636
20.

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.

van Genugten RE, van Raalte DH, Diamant M.

Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1:S26-34. doi: 10.1016/S0168-8227(09)70006-3.

PMID:
20115929

Supplemental Content

Support Center